This is a rare inherited disease. It affects how the body breaks down certain fats and sugars. The body doesn't have enough of a special enzyme called a sulfatase. This leads to a buildup of these substances in the body, especially in the brain and nerves. This buildup causes problems with movement, vision, and other functions, often starting in childhood.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Multiple sulfatase deficiency (MSD) is an ultra-rare inherited disease that causes progressive damage to the brain and nervous system, along with problems in the skeleton, skin, eyes, hearing, heart, airway and other organs. It usually begins in infancy or early childhood. Children may develop slowly at first and then lose skills they had gained, such as walking, talking, seeing or hearing. The name describes the problem. Sulfatases are a family of enzymes that break down sulfate-containing fats and sugars inside cells. In MSD, the body cannot switch these enzymes on, so all of them work poorly at once. The material they normally clear builds up and harms tissues. Because several separate rare diseases are each caused by losing just one sulfatase, MSD combines features of them: nerve damage resembling metachromatic leukodystrophy, skeletal and facial changes resembling the mucopolysaccharidoses (often shortened to MPS), and dry, scaly skin called ichthyosis. MSD varies a great deal. A very severe neonatal form shows signs at or before birth. An infantile form, the most common, ranges from severe to more slowly progressing (attenuated). A rare juvenile form begins later in childhood and moves more slowly still.
MSD is caused by changes (variants) in both copies of a gene called SUMF1. This gene makes the enzyme that activates every sulfatase in the body, which is why one gene can affect so many systems. Nothing a parent did during pregnancy causes MSD, and there are no environmental triggers. The condition is inherited in an autosomal recessive pattern. Each parent usually carries one altered copy of SUMF1 and is healthy. When both parents are carriers, each pregnancy has a 25% (one in four) chance of a child with MSD, a 50% chance of a child who is a healthy carrier, and a 25% chance of a child who neither has the condition nor carries it. Once a family's specific variants are known, carrier testing for relatives and testing during future pregnancies are possible. Some variants tend to cause milder disease than others, but the gene result alone cannot predict one child's course precisely.
MSD is often suspected when a young child has developmental delay or loss of skills together with features such as ichthyosis, coarse facial features, an enlarged liver and spleen, or skeletal changes on X-ray. Brain MRI (magnetic resonance imaging) may show damage to the white matter, the brain's wiring, similar to a leukodystrophy. The diagnosis is confirmed in two ways. Blood or skin-cell tests show low activity of at least two different sulfatase enzymes, and genetic testing finds disease-causing variants in both copies of SUMF1. Urine tests may show several kinds of stored sulfated material at once, which points strongly toward MSD, although not every child has this finding. Each test can miss MSD on its own. A panel that measures only one or two enzymes can be misleading, enzyme levels can vary over time, and some genetic changes are hard to detect or interpret. Specialists therefore recommend combining genetic testing with measurement of at least three sulfatases. Because MSD is so rare, children are often diagnosed after other conditions have been considered.
There is no approved treatment that targets the cause of MSD and no cure. Care aims to manage each complication early, keep the child as comfortable and capable as possible, and support the family. A team led by a metabolic or genetics specialist typically coordinates neurology, cardiology, eye, hearing, airway, orthopedic, nutrition and therapy services, following an expert consensus framework. Much of that care is the standard treatment for each problem: seizure medicines, management of muscle stiffness (spasticity), hearing aids, eye care, and physical, occupational and speech therapy. Feeding often becomes difficult, and many children eventually need a feeding tube to get enough nutrition safely. Vitamin D and weight-bearing activity help support weak bones. Sleep apnea may be treated with breathing support at night or with surgery on the tonsils and adenoids, though surgery carries a higher complication rate in MSD. Fluid buildup around the brain (hydrocephalus) can develop and may need surgical treatment. Anesthesia needs special planning. The airway often narrows over time and the bones of the neck can be unstable, so tilting the head back, including for placing a breathing tube, can compress the spinal cord. Every anesthesia team should know the diagnosis in advance, and neck imaging is recommended before any procedure that requires neck extension. Research is active. A few children with attenuated MSD have received a blood stem cell (bone marrow) transplant, with improved laboratory markers and signs of slower progression, but long-term benefit is not yet known. Gene therapy has so far been tested only in animals. Families may ask whether a clinical trial or research registry is open to them.
MSD is progressive, and its pace varies widely. In severe forms, children may reach few milestones and lose skills quickly. In attenuated forms, a child may learn to walk and speak and lose those abilities more slowly over years. Children who walk independently and whose symptoms begin later tend to do better. MSD shortens life: in a study of 35 people with MSD, the median age at death was 13 years, and the neonatal form is often fatal in the first two years. These figures describe groups, not any one child. Daily life usually involves many appointments and growing care needs: feeding support, managing seizures and stiffness, positioning and mobility equipment, and help with sleep. Regular monitoring often includes yearly heart, eye and hearing checks, vitamin D levels, head size measurements and imaging when symptoms change. The emotional and practical load on families is heavy, and early connection with palliative care, respite services and rare disease groups can make planning and day-to-day care more manageable.
Ask for a genetics or metabolic evaluation if a young child has developmental delay or is losing skills, especially alongside very dry, scaly skin, coarse facial features or skeletal changes. Relatives of a person with MSD who are planning a pregnancy can ask about carrier testing. For a child already diagnosed, contact the care team promptly about new or more frequent seizures, a sudden loss of skills, worsening feeding or frequent choking or coughing with meals, loud snoring or pauses in breathing during sleep, new weakness or numbness in the arms or legs, or a head that is growing faster than expected. Before any surgery, dental work under sedation or scan that needs anesthesia, make sure the team knows about MSD and its airway and neck risks.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Multiple Sulfatase Deficiency is like, what's helped you, or ask the community a question.